Novartis AG (SWX: NOVN)
100.92
-0.44 (-0.43%)
Sep 4, 2024, 5:30 PM CET
Novartis AG Revenue
Novartis AG had revenue of $12.87B USD in the quarter ending June 30, 2024, with 9.60% growth. This brings the company's revenue in the last twelve months to $48.86B, up 9.70% year-over-year. In the year 2023, Novartis AG had annual revenue of $46.66B with 7.36% growth.
Revenue (ttm)
$48.86B
Revenue Growth
+9.70%
P/S Ratio
4.73
Revenue / Employee
$642.41K
Employees
76,057
Market Cap
205.21B CHF
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
Dec 31, 2019 | 48.68B | 2.58B | 5.59% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNovartis AG News
- 6 hours ago - Novartis expands U.S. radiopharma production amid rising competition - Seeking Alpha
- 6 days ago - Competitor Analysis: Evaluating Johnson & Johnson And Competitors In Pharmaceuticals Industry - Benzinga
- 6 days ago - Natco Pharma submits ANDA for generic version of Tabrecta, a $126M US market drug - Business Upturn
- 7 days ago - Comparing Merck & Co With Industry Competitors In Pharmaceuticals Industry - Benzinga
- 7 days ago - Novartis' Cholesterol-Lowering Drug Shows Encouraging Outcome In Late-Stage Study - Benzinga
- 7 days ago - Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation - Business Wire
- 7 days ago - Novartis twice-yearly* Leqvio® demonstrated clinically meaningful, statistically significant LDL-C lowering as a monotherapy in patients at low or moderate ASCVD risk - GlobeNewsWire
- 9 days ago - Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats - Investor's Business Daily